Scientific split - the human genome breakthrough dividing former colleagues
Two groups are racing to establish scientific and commercial priority over the discovery of the decade
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Friday 25 April 2014
The money men have moved in on a new technique for editing the human genome that promises to revolutionise the way many human diseases will be treated in the future. But Big Money has in the process divided a scientific community into two competing camps.
Some might see it has healthy scientific rivalry spilling over into commercial competition which could ultimately speed up medical innovation. But behind closed doors there is a desperate race to establish scientific and commercial priority over what could be the scientific discovery – and intellectual property – of the decade.
On the one side is a consortium of world-class researchers led by French-born Professor Emmanuelle Charpentier who made a key discovery behind the Crispr gene editing technique and has been promised $25m (£16m) by a group of venture capitalists to commercialise her invention for medical use.
On the other side is her former colleague and the co-discoverer of the gene-editing process, Professor Jennifer Doudna of the University of California, Berkeley, who has joined a rival consortium of researchers with $43m in venture capital to advance the Crispr technique into the clinic.
Each group has recruited a formidable panel of senior scientists as advisers. The Charpentier team, called Crispr Therapeutics, includes Nobel Laureate Craig Mello, the co-discoverer of a gene-silencing technique known as RNAi, and Daniel Anderson of the Massachusetts Institute of Technology, who was the first person to show that Crispr can cure a genetic disease in an adult animal.
Meanwhile the Doudna team, known as Editas Medicine, includes the Harvard geneticist George Church, a pioneer in synthetic biology, and Feng Zhang of MIT and the Broad Institute, who successfully managed to get Crispr to work in human cells and was this month awarded the first US patent on the technique – much to the dismay of Professor Charpentier.
“I have to be careful what I say here. It is very surprising. But the fundamental discovery comes from my laboratory and no-one has told me that they have scooped me,” Professor Charpentier told The Independent.
“Be certain that this discovery did not happen only by chance. I have been thinking, defending and carrying this study from Austria to Sweden and now Germany,” she said.
Patent attorneys are now pouring over the rival patent applications, in particular the claims relating to who has priority over a key element of the Crispr technique called Cas9, a bacterial gene for an enzyme that snips both strands of the DNA double helix at the same place – a key feature of the gene-editing process.
Professor Charpentier said that she identified Cas9, the most important fundamental discovery behind Crispr (pronounced “crisper”), when she worked at Umea University in Sweden, before she had teamed up with Professor Doudna to co-author a scientific paper on Crispr-Cas9 published in August 2012 in the journal Science.
Professor Charpentier, who is now at the Hannover Medical School in Germany, said that Cas9 was in fact described for the first time in an earlier scientific paper, published in Nature in March 2011, under its former name of Csn1, which she had isolated from the bacterium Steptococcus pyogenes.
“I was the scientist who described the technology and I kept the intellectual property when I was in Sweden….Editas does not have access to the intellectual property of the patent where I’m the co-inventor,” Professor Charpentier said.
“I made the decision to do something in Europe and I made the decision not to do something with Editas Medicine. I’m trying to remain true to myself….The aim is to use Crispr-Cas9 as a kind of genetic medicine to treat serious diseases. The point about Cas9 is that it works in every cell and in every organism tested – it’s mind blowing,” she said.
For her part, Professor Doudna said there is room for both camps to develop new medical therapies based on Crispr-Cas9.
“Emmanuelle and I are excited to see this platform employed to help patients, and there are of course many different targets and strategies to be taken, providing opportunities for multiple companies in this space,” Professor Doudna said.
“In addition to start-ups, many existing companies are also interested in using the technology for various applications that extend beyond human therapeutics. I expect that the commercial landscape will continue to evolve as the technology matures,” she said.
The main barrier to using Crispr-Cas9, however, will be its safe and efficient delivery to the cells and tissues that need the genetic therapy. Professor Mello believes that the first treatments are likely to involve the genetic manipulation of stem cells in the laboratory, before transplantation back into the affected parts of the body.
“Delivery to cells within the context of the whole body, brain or other organ is very difficult and inefficient… This is why Crispr therapies will no doubt be limited for the foreseeable future to applications where stem cells can be modified one, or a few, at a time and then reintroduced after double checking that only the intended change was made,” Professor Mello said.
WHAT IS CRISPR?
The human genome consists of a long sequence of "letters" written in the code of the genetic alphabet - the three billion base-pairs of the DNA molecule. The gene-editing technique known as Crispr-Cas9 is able for the first time to delete or swap any of these letters, right down to changing a single base pair at any designated place in the genome.
Crispr, which stands for clustered regularly interspaced short palindromic repeats, was originally discovered as a kind of immune system in bacteria to defend against invading viruses. Its potential for editing the genomes of animals, including humans, only came with the discovery of the Cas9 gene, an enzyme for cutting both strands of DNA, found in the bacterium Streptococcus pyogenes.
The commercial applications of Crispr, which could extend to treating genetic diseases and cancer, will depend to a great extent on Cas9 and who owns the intellectual property on this part of the invention. This is why patent disputes are likely to focus on who did what and when in terms of the Cas9 discovery. Emmanuelle Charpentier of Hannover Medical School in Germany and Jennifer Doudna of the University of California, Berkeley are both named as co-inventors on one patent.
- 1 The black and blue dress: Makers considering a white and gold version
- 2 Husband and wife die holding hands within hours of each other after 67 years of marriage
- 3 PornHub turns masturbation into energy in bid to save the planet
- 4 The remarkable archaeological underwater discovery that could open up a new chapter in the study of European and British prehistory
- 5 Saudi Muslim cleric claims the Earth is 'stationary' and the sun rotates around it
Boris Nemtsov shot dead: Putin critic may have been murdered by Islamic extremists, says president-led committee
Stephen Hawking's wife Jane Wilde on their marriage breakdown: 'The family were left behind'
British are sexually uptight, dirty and drink too much – according to Spanish book
PornHub turns masturbation into energy in bid to save the planet
White and gold or blue and black – what colour is the dress? An eyewitness gives a definitive answer
New theory could prove how life began and disprove God
This is what it's like to be dead, according to a guy who died for a bit
'Cash for access' scandal: Sir Malcolm Rifkind says 'unrealistic' for MPs to live on £67,000 salary
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
Ukip would cut billions from Scottish budget to fund English tax cuts
Russia's roadmap for annexing eastern Ukraine 'leaked from Vladimir Putin's office'
£9 per hour: Recruitment Genius: This role is based within a small family run ...
£28000 - £32000 per annum: Recruitment Genius: This Design and marketing agenc...
£46000 per annum: Recruitment Genius: This property investment firm are lookin...
£18000 - £35000 per annum: Recruitment Genius: This company specialises provid...